NASDAQ
DRIO
Last Price
US $6.53
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
DarioHealth Corp. cash flow to debt ratio of -81.71% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial stability - Healthy cash flow growth.
DarioHealth Corp.'s free cash flow has increased -32.60% from $-38.70M last year to $-26.08M, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
DarioHealth Corp.'s debt to equity ratio is 0.51, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial risk - Healthy debt to equity ratio development.
DarioHealth Corp.'s debt has increased relative to shareholder equity from 0.42 last year to 0.51 today, signaling weakened financials
Financial risk - Net debt/EBITDA.
DarioHealth Corp. has negative EBITDA, making leverage ratio unreliable
Financial risk - ICR.
DarioHealth Corp.'s interest coverage ratio is -11.87, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial stability - Profit margin growth.
DarioHealth Corp.'s profit margin has increased (-287.20%) in the last year from -158.09% to 295.94%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
DarioHealth Corp.'s short-term assets of $34.81M exceed its short-term liabilities of $9.32M
Decreasing performance - ROA.
DarioHealth Corp.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Increasing performance - Absolute return on equity.
DarioHealth Corp.'s return on equity of 93.18%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
DarioHealth Corp.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
DarioHealth Corp. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
DarioHealth Corp. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
DarioHealth Corp. has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
DarioHealth Corp.'s yearly earnings has increased -2.42% since last year from $-42.75M to $-41.71M, signaling increasing performance
Decreasing performance - Healthy revenue growth.
DarioHealth Corp.'s yearly revenue has decreased -17.31% since last year from $27.04M to $22.36M, signaling decreasing performance
Decreasing performance - ROIC.
ROIC -56.57% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
DarioHealth Corp.'s 3-year revenue CAGR of -6.84% is negative, indicating declining revenue over the past 3 years
Increasing performance - Revenue consistency.
DarioHealth Corp. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
DarioHealth Corp. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
DarioHealth Corp. has insufficient data to evaluate this check.
Undervalued - Earnings yield.
DarioHealth Corp. has an earnings yield of 19.35%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Overvalued - EBITDA valuation.
DarioHealth Corp. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
DarioHealth Corp. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Undervalued - PEG ratio value.
DarioHealth Corp. has a PEG-ratio under 1 which is considered undervalued
Overvalued - P/B ratio.
DarioHealth Corp. has a price-to-book ratio of 5.20x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value
Overvalued - P/S ratio.
DarioHealth Corp. has a price-to-sales ratio of 15.29x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
93.18%
Return on equity
ROIC: -56.57%
Valuation History
2.2X
Price to Earnings
EV/EBITDA: -2X
Cash flow
Profit margin
24.17%
(FY vs FY)
EBITDA Y/Y
-3.05%
(FY vs FY)
Cash flow Y/Y
-7.30%
(FY vs FY)
Fair Value
Market $6.53
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.